Protein Clinical Trials

164 recruitingLast updated: June 18, 2026

There are 164 actively recruiting protein clinical trials across 52 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Baltimore, Maryland, United States. Updated daily from ClinicalTrials.gov.


Protein Trials at a Glance

164 actively recruiting trials for protein are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 59 trials, with the heaviest enrollment activity in Houston, New York, and Baltimore. Lead sponsors running protein studies include Zhujiang Hospital, Texas A&M University, and Maastricht University Medical Center.

Treatments under study

About Protein Clinical Trials

Looking for clinical trials for Protein? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Protein trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Protein clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 164 trials

Recruiting

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

Kidney CancerKidney NeoplasmsPneumothorax+1 more
National Cancer Institute (NCI)950 enrolled1 locationNCT00033137
Recruiting

Cohort Study on Neuroimmune Diseases in the Reproductive Age

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+3 more
Third Affiliated Hospital, Sun Yat-Sen University100 enrolled1 locationNCT07653984
Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Familial CancerMesotheliomaBRCA1-Associated Protein-1 (BAP1) Mutations+1 more
National Cancer Institute (NCI)300 enrolled1 locationNCT04431024
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 2

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Proteinuric Kidney Diseases
Boehringer Ingelheim132 enrolled156 locationsNCT07355296
Recruiting
Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled28 locationsNCT06695845
Recruiting
Phase 2

A Study of DII235 in Adults With Elevated Lipoprotein(a)

Lipoprotein Disorder
Novartis Pharmaceuticals200 enrolled66 locationsNCT07235046
Recruiting
Phase 2Phase 3

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated466 enrolled318 locationsNCT05312879
Recruiting

Baker Gordon Syndrome Natural History Study

Rare DiseasesSleep DisorderAutism or Autistic Traits+4 more
University of Missouri-Columbia50 enrolled1 locationNCT06399952
Recruiting
Phase 3

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Chronic Kidney DiseaseProteinuriaChildren
Bayer100 enrolled179 locationsNCT05457283
Recruiting
Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines392 enrolled46 locationsNCT06427941
Recruiting

Effect of Protein Dosage on Persistent Acute Renal Failure in Critically Ill Patients.

Critical IllnessAcute Kidney FailureNutritional Support+2 more
Hospital Italiano de Buenos Aires344 enrolled6 locationsNCT07631221
Recruiting
Not Applicable

Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome

Food Protein Induced Enterocolitis Syndrome
NYU Langone Health72 enrolled2 locationsNCT06683521
Recruiting
Not Applicable

Investigating the Effects of Beef Consumption on Cognitive and Brain Health

Dietary ProteinsDietary InterventionCognitive Ability, General+1 more
University of Nebraska Lincoln240 enrolled1 locationNCT06690892
Recruiting

Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic Disease

EpilepsyGlucose Metabolism DisordersGlut1 Deficiency Syndrome 1+4 more
Weill Medical College of Cornell University20 enrolled2 locationsNCT05085704
Recruiting
Phase 2

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+5 more
M.D. Anderson Cancer Center90 enrolled1 locationNCT03263572
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche152 enrolled82 locationsNCT05271409
Recruiting
Not Applicable

Clinical Trial On The Effect Of Artisterol On Risk Factors In Individuals With Suboptimal Cholesterol Levels

Hyperlipoproteinemia
Zentiva, k.s.106 enrolled1 locationNCT07405814